Recruiting studies: Third Line And Beyond Therapy

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Study of Pazopanib Combined With Palbociclib for Refractory Solid Tumors With Co-amplified in the 11q13(FGF3/4/19/CCND1)
Phase 1/Phase 2 · 1 location(s) · Tianjin Medical University Second Hospital · NCT06895733 Low-dose Trifluridine/Tipiracil With Bevacizumab in mCRC
Phase 2 · 2 location(s) · Ruijin Hospital · NCT07085169 Efficacy and Safety of Vorolanib Monotherapy As Third-line or Later Treatment for Advanced Non-small Cell Lung Cancer Pa
Phase 2 · 1 location(s) · Li-kun Chen · NCT06728852 The Aim of This Study is to Assess the Efficacy and Safety of Chidamide, Regorafenib in Combination With Iparomlimab and
Phase 2 · 1 location(s) · Shanghai Changzheng Hospital · NCT06930118

Look up another condition

Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.